Example: Heart Attack

Search clinical trials for: Reaferon

Total 404 results

NCT03547154

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Conditions: Chronic Myelogenous Leukemia
NCT02343224

Recruiting

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Conditions: Juvenile Pilocytic Astrocytomas; Optic Pathway Gliomas
NCT03552549

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Conditions: Melanoma
NCT00686478

Withdrawn

Intron A for the Treatment of Hypertrophic Scar

Conditions: Burn; Hypertrophic Scar
NCT02634294

Recruiting

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Conditions: Hematological Neoplasms; Recurrence
NCT02199327

Completed

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Conditions: Conjunctival Intraepithelial Neoplasia; Corneal Intraepithelial Neoplasia
NCT00561912

Terminated

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Conditions: Renal Cell Carcinoma
NCT01943422

Completed

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

Conditions: Melanoma
NCT02323659

Unknown status

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Conditions: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
NCT00588146

Terminated

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

Conditions: Anemia; Liver Disease; Hypoxemia
NCT00629200

Completed

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Conditions: Advanced Cancer; Solid Tumors
NCT01325896

Unknown status

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Conditions: Multiple Mieloma
NCT00723710

Completed

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Conditions: Melanoma
NCT00378599

Completed

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

Conditions: Liver Transplantation; Hepatitis C, Chronic; Liver Cirrhosis
NCT03537274

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Conditions: Hepatitis C
NCT00085384

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
NCT00179413

Completed

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

Conditions: Hepatitis C Virus; Advanced Fibrosis; Cirrhosis
NCT00727077

Terminated

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Conditions: Hepatitis C, Chronic; Hepatitis C
NCT04226950

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia

Conditions: Essential Thrombocytopenia
NCT03435302

Unknown status

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Conditions: Melanoma
NCT01462773

Completed

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Conditions: Melanoma
NCT00886457

Terminated

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Conditions: Cancer
NCT00037882

Terminated

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Conditions: Leukemia, Myeloid, Philadelphia-Positive
NCT00525031

Completed

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Conditions: Melanoma
NCT02339324

Active, not recruiting

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Conditions: Melanoma